<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report transcatheter aortic valve implantation (TAVI) for pure <z:mp ids='MP_0006047'>aortic valve insufficiency</z:mp> in a patient with an otherwise <z:mpath ids='MPATH_458'>normal</z:mpath> aortic valve and a long-term left ventricular assist device (LVAD) </plain></SENT>
<SENT sid="1" pm="."><plain>An oversized 29-mm <z:e sem="disease" ids="C0152096" disease_type="Disease or Syndrome" abbrv="">Edwards</z:e> SAPIEN valve (<z:e sem="disease" ids="C0152096" disease_type="Disease or Syndrome" abbrv="">Edwards</z:e> Lifesciences, Irvine, CA) was implanted in the 21-mm native aortic valve annulus </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the complete absence of <z:mp ids='MP_0010522'>aortic calcifications</z:mp>, the prosthesis remained stably anchored inside the annulus </plain></SENT>
<SENT sid="3" pm="."><plain>The reported experience demonstrates that TAVI is feasible even in patients with pure <z:hpo ids='HP_0001659'>aortic valve regurgitation</z:hpo> and can be a reasonable option in patients with <z:hpo ids='HP_0001659'>aortic regurgitation</z:hpo> after LVAD implantation </plain></SENT>
</text></document>